# EDGAR Filing Document

**Accession Number:** 0001781983
**File Stem:** 0001104659-23-019906
**Filing Date:** 2023-2
**Character Count:** 5156
**Document Hash:** f82bd6ebdd067accdcb60b8391da7d68
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-019906.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001104659-23-019906

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230210

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aprea Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001781983
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39069
- **FILM NUMBER:** 23620291

**BUSINESS ADDRESS:**
- **STREET 1:** 3805 OLD EASTON ROAD
- **CITY:** DOYLESTOWN
- **STATE:** PA
- **ZIP:** 18902
- **BUSINESS PHONE:** 267-370-5219

**MAIL ADDRESS:**
- **STREET 1:** 3805 OLD EASTON ROAD
- **CITY:** DOYLESTOWN
- **STATE:** PA
- **ZIP:** 18902

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**February 10, 2023**

Date of Report (Date of earliest event reported)

**Aprea Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**001-39069** | &nbsp;&nbsp;**001-39069** | &nbsp;&nbsp;**84-2246769** |
| &nbsp;&nbsp;(State or other jurisdiction<br> of incorporation) | &nbsp;&nbsp;(Commission<br> File Number) | &nbsp;&nbsp;(Commission<br> File Number) | &nbsp;&nbsp;(IRS Employer<br> Identification No.) |
| &nbsp;&nbsp;**3805 Old Easton Road**<br> **Doylestown** **, PA**<br> (Address of principal executive offices) | &nbsp;&nbsp;**3805 Old Easton Road**<br> **Doylestown** **, PA**<br> (Address of principal executive offices) | &nbsp;&nbsp;<br> **18902**<br> (Zip Code) | &nbsp;&nbsp;<br> **18902**<br> (Zip Code) |

---

&nbsp;&nbsp;Registrant's telephone number, including area code: **(617) 463-9385**<br>(Former name or former address, if changed since last report):<br>

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on** <br> **which registered**  |
| Common stock, par value $0.001 per share | APRE | NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ⌧

**Item 8.01 Other Events.**

As previously disclosed, Aprea Therapeutics, Inc. (the "Company") filed an amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware, to effect a one-for-twenty reverse stock split, effective as of 5:00 p.m. on February 10, 2023 (the "Reverse Split"). At 7:50 p.m. on February 10, 2023, Nasdaq halted trading in the Company's common stock pending the release of material news related to the Reverse Split. Nasdaq has informed the Company that (i) the halt in trading was purely administrative in nature to ensure market vendors had ample time to adapt to the Reverse Split and (ii) trading in the Company's common stock is expected to resume at 9:45 a.m. on February 14, 2023.

**Item 9.01. Financial Statements and Exhibits.**

(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exhibits</u>.

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Aprea Therapeutics, Inc.** | **Aprea Therapeutics, Inc.** |
| Dated: February 13, 2023 | By: | /s/ Oren Gilad |
|  | Name: | Oren Gilad |
|  | Title: | President and Chief Executive Officer |

---